We are an international and independent pharmaceutical company governed by a non-profit foundation, with headquarters in Suresnes, France. Since opening our first laboratory in 1954, we have been committed to therapeutic progress to serve patient needs with the help of healthcare professionals. We strive to provide future generations with a world where quality healthcare is available and accessible to all.
Operating in 148 countries, we have 21,000 collaborators employed worldwide and a turnover of 4 billion euros in 2016. Entirely independent, we are able to reinvest 25% of our total revenue (excluding generics) into Research and Development, and all profits are used for further development.
Corporate growth at Servier is driven by our continuous pursuit of innovation in five areas of excellence: cardiovascular and immune-inflammatory diseases, neuropsychiatric disorders, oncology and diabetes. We are a leading force in cardiology—number 2 in Europe, number 8 worldwide—and oncology has become a top priority in recent years; we also manufacture high-quality generic drugs.
Contact
Address: bul. “Tsar Osvoboditel” 14, 1000 Sofia Center, Sofia (Bulgaria)
Tel. +359 2 921 57 00
Website: http://www.servier.
Aurélien Breton, general manager at Servier Bulgaria, explains how the affiliate has performed under his tenure and highlights the importance of combining the right portfolio with a top-notch team to…
In recent years, global pharma’s Business Development (BD) operations in Asia have evolved from primarily managing global agreements locally to engaging in more complex tasks like contract negotiation and due…
With revenues projected to reach USD 27.01 billion in 2024, France’s pharma market is ranked fifth globally. Home to a number of well-established local pharma players and a sought-after destination…
Drawing on over 30 years of industry experience across a wide range of global markets, Pierre Perez today adopts an open-minded approach to leading Servier’s operations in India. Having fostered…
Portugal boasts a well-developed universal healthcare system and saw healthcare spending increase by 6.2 percent annually between 2016 and 2021, according to the OECD. However, the representatives of innovative medicines…
Speaking from Servier’s new open-plan office in Lisbon, a space aimed at promoting cross-functional integration and “collective intelligence,” experienced industry executive Frédéric Bengold looks back on three successful years at…
France’s life sciences industry is falling behind its European neighbours, its growth deeply hampered, the French life sciences think tank G5 Santé claims, by abusive paybacks. While the government has…
Servier Morocco, with its robust portfolio of 15 products and a turnover of EUR 30 million, has forged a leading position in the local market. Managing Director Florent Darchez explains…
The latest news from French healthcare and pharma, including an update on the hospital crisis; MaaT Pharma and Skyepharma’s new cGMP microbiome facility; Sanofi’s offloading of central nervous system drugs…
Encircled by heavyweight life sciences powerhouses of the likes of Germany, France and Switzerland, plucky Belgium nonetheless continues to astonish and project considerable influence when it comes to its abilities…
Pierre Boyer, GM at Servier BeLux for the past six years, outlines the unique characteristics and challenges of the Belgian market and shares the company’s 2030 strategy, its unique approach…
French mid-cap Servier has launched a new visual identity and logo and announced an ambitious 2030 growth plan with an increased focus on hard-to-treat cancers. Servier, which is governed…
Servier’s Estève Speranza outlines the rationale behind the French group’s reorganisation in the Nordic countries, how the global shift towards oncology is playing out in his region, and the Nordics’…
See our Cookie Privacy Policy Here
